Posts By: pharmanewsdaily

LABORIE to acquire Clinical Innovations from EQT for $525m

LABORIE acquisition of Clinical Innovations : LABORIE Medical Technologies has agreed to acquire Utah-based Clinical Innovations for $525 million from EQT Mid Market US fund and the EQT Mid Market Asia III fund (jointly EQT). Headquartered in Salt Lake City, Clinical Innovations provides medical devices for the labor and delivery (L&D) and neonatal intensive care […]

J&J takeover of Verb Surgical : J&J strikes deal with Verily for full ownership in robotic surgery company

J&J takeover of Verb Surgical : Johnson & Johnson (J&J) has agreed to take full ownership in US robotic surgery company Verb Surgical by acquiring the remaining stake it previously did not own from its joint venture partner Verily Life Sciences, an Alphabet company. The joint venture for the development of surgical robotic systems was […]

Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798

Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Roche’s cancer drug Rituxan (rituximab). Rituxan, which is a CD20-directed cytolytic antibody, has approval across various regions for the […]

Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer

Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) for the treatment of advanced urothelial cancer, the most common form of bladder cancer. Padcev, which has been co-developed by the two pharma companies, is a Nectin-4-directed antibody and microtubule […]

HemaCare to be acquired by Charles River Laboratories for $380m

Charles River acquisition of HemaCare : Charles River Laboratories International, an early-stage contract research organization, has agreed to acquire HemaCare for about $380 million in an all-cash deal, as per the latest pharma acquisition news. HemaCare is engaged in the production of human-derived cellular products for the cell therapy market. The company provides critical biomaterials, […]

Amarin bags Vascepa FDA approval for reducing cardiovascular risk

Vascepa FDA approval : New Jersey-based Amarin has secured approval from the US Food and Drug Administration (FDA) for a new indication and label expansion for Vascepa (icosapent ethyl) capsules. The FDA has now approved Vascepa as an adjunctive (secondary) therapy to cut down the risk of cardiovascular events in adults having elevated triglyceride levels, […]

Glaukos closes Avedro acquisition to expand corneal health franchise

Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in Waltham, Massachusetts, Avedro is a hybrid ophthalmic pharmaceutical and medical technology company, which is focused on treating corneal disease and disorders and enhancing vision to decrease dependency on eyeglasses or […]

CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m

Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics technology company, from US medical device company Hologic. Based in Massachusetts, Cynosure provides medical aesthetic treatment systems for plastic surgeons, dermatologists, medical spas and other healthcare practitioners. Cynosure’s product portfolio […]

3M to sell drug delivery business to Altaris Capital for $650m

US industrial conglomerate 3M has signed a cash-cum-stock deal worth around $650 million to sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650 million, as per the latest pharma acquisition news. As per the terms of the deal, the total consideration includes cash, an interest-bearing security, […]

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Scroll To Top